Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Trial Profile

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SONICS
  • Sponsors Strongbridge Biopharma
  • Most Recent Events

    • 25 Mar 2019 According to a Strongbridge Biopharma media release, secondary endpoint results were presented at the 16th Annual International Pituitary Congress (IPC).
    • 25 Mar 2019 Results presented in a Strongbridge Biopharma media release.
    • 18 Mar 2019 Results of subgroup analysis of Cushings syndrome (CS) patients with diabetes mellitus (DM), were presented at the 101st Annual Meeting of the Endocrine Society (ENDO 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top